GENVOYA Drug Patent Profile

Which patents cover Genvoya, and what generic alternatives are available?

Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and sixty-three patent family members in fifty-three countries.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Genvoya

Genvoya was eligible for patent challenges on November 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 6, 2033. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GENVOYA

International Patents:	463
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GENVOYA

Paragraph IV (Patent) Challenges for GENVOYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GENVOYA	Tablets	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	150 mg/150 mg/ 200 mg/10 mg	207561	1	2023-04-12

US Patents and Regulatory Information for GENVOYA

GENVOYA is protected by nine US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes					Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes					Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes					Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes					Y
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes					Y

International Patents for GENVOYA

When does loss-of-exclusivity occur for GENVOYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Peru

Poland

Portugal

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GENVOYA around the world.

Country	Patent Number	Title	Estimated Expiration
Ukraine	101193	ПРИМЕНЕНИЕ ЧАСТИЧЕК ТВЕРДОГО НОСИТЕЛЯ ДЛЯ УЛУЧШЕНИЯ ТЕХНОЛОГИЧЕСКИХ ХАРАКТЕРИСТИК ФАРМАЦЕВТИЧЕСКОГО АГЕНТА;ЗАСТОСУВАННЯ ЧАСТИНОК ТВЕРДОГО НОСІЯ ДЛЯ ПОЛІПШЕННЯ ТЕХНОЛОГІЧНИХ ХАРАКТЕРИСТИК ФАРМАЦЕВТИЧНОГО АГЕНТА (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Japan	2015078241	治療薬の薬物動態特性の調節 (ADJUSTMENT OF PHARMACOKINETICS OF CURATIVE MEDICINE)
Hungary	E031707
Spain	2329240
World Intellectual Property Organization (WIPO)	2005112930

Supplementary Protection Certificates for GENVOYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3150586	PA2020508	Lithuania		PRODUCT NAME: KOBICISTANAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS, DARUNAVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS, YPAC DARUNAVIRO ETANOLATAS, IR EMTRICITABINAS, ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/17/1225 20170921
1564210	132013902209844	Italy		PRODUCT NAME: COMPRENDENTE IL PRODOTTO ELVITEGRAVIR COME UNO DEI PRINCIPI ATTIV(STRIBILD); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/830/001-002, 20130524
3150586	122020000022	Germany		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND EMTRICITABIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/17/1225 20170921
2487163	93353	Luxembourg		PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE D'ATAZANAVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1025
3150586	18/2020	Austria		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, DARUNAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, INSBESONDERE DARUNAVIRETHANOLAT, UND EMTRICITABIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/17/1225 20170925

GENVOYA: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

GENVOYA (emtricitabine, rilpivirine, and tenofovir alafenamide) is a branded combination antiretroviral therapy (ART) for the treatment of HIV-1. Approved by the U.S. Food and Drug Administration (FDA) in 2016 by Gilead Sciences, GENVOYA has established a significant position within the HIV therapeutic market due to its efficacy, favorable safety profile, and patient adherence benefits. This report analyzes the investment potential, market dynamics, and future financial trajectory of GENVOYA, emphasizing competitive landscape, market penetration, regulatory environment, and pricing strategies.

---

1. Market Overview and Growth Drivers

Global HIV Therapy Market

Parameter	Value / Projection
2022 global HIV market size	~$22 billion [1]
CAGR (2022-2027)	4.2% [1]
Predicted market size (2027)	~$27.4 billion
Leading product segments	Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Integrase Inhibitors (INSTIs) [2]

Key Drivers for GENVOYA’s Market Penetration

• Efficacy and Safety: GENVOYA’s long-term safety profile promotes adherence—critical in HIV management.
• Simplified Regimen: Once-daily, single-pill formulation enhances compliance versus multi-drug regimens.
• Brand Recognition: Gilead’s established market presence supports trust and prescriber preference.
• Regulatory Approvals: Multiple regional approvals (e.g., EMA, PMDA) extend global accessibility.
• Pricing and Reimbursement: Adjusted to regional economic parameters; Gilead’s market access strategies favor broad uptake.

---

2. Market Dynamics and Competitive Landscape

Therapeutic Alternatives and Competitors

Product/Brand	Active Ingredients	Approval Year	Market Share (2022)	Distinctive Features
Genvoya	Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide	2015	~38%	Similar to GENVOYA; also includes booster, marketed with a fixed-dose combination (FDC)
Truvada	Emtricitabine, tenofovir disoproxil fumarate	2004	~15%	Older formulation; replaced partly by GENVOYA for safety/efficacy reasons
Biktarvy	Bictegravir, emtricitabine, tenofovir alafenamide	2018	~28%	Higher barrier to resistance, favored in some regions
Other generics and biosimilars	Various	N/A	Growing	Price-sensitive markets shifting toward generics

Market Share Trends and Competition

Gilead’s portfolio dominance remains challenged by newer INSTI-based therapies with better resistance profiles, safety, and dosing convenience. The shift toward integrase inhibitors has increased competition, especially with Biktarvy’s rapid growth and favorable profile.

Regulatory and Reimbursement Influences

• Patent Status: Patent exclusivity for Genvoya and GENVOYA extends through 2027 in the U.S., after which generics are expected.
• Pricing Strategies: Gilead faces downward pressure; however, premium pricing persists in developed markets due to brand equity.

---

3. Financial Trajectory and Investment Outlook

Sales and Revenue Trends

Year	Estimated Sales (USD Millions)	Notes
2018	~$2,800	Launch year, increased uptake
2019	~$3,400	Market expansion continues
2020	~$3,700	COVID-19 impact; increased adherence in some cases
2021	~$3,900	Slight growth, new regional approvals
2022	~$4,100	Mature market phase, gradual growth

Projection 2023–2027

Year	Projected Sales (USD Millions)	Assumptions
2023	~$4,300	Patent extension, stable adherence
2024	~$4,500	Potential biosimilar entry in select markets
2025	~$4,600	Competition intensifies, market saturation
2026	~$4,500	Entry of generics in mature regions, price reductions
2027	~$4,200	Decline due to patent expiry and generic competition

Note: These projections consider regional growth variability and assumed patient adherence levels.

Key Revenue Drivers

• Market Penetration: Continued adoption in developed markets.
• Pricing Strategies: Value-based pricing and reimbursement negotiations.
• Patent and Exclusivity: Patent expiry approaching in 2027; impacts future revenue.
• Global Expansion: Growing markets in Asia-Pacific, Africa, and Latin America.

Investment Considerations

Factor	Implication
Patent expiration	Potential revenue decline post-2027 (biosimilars expected)
Competitive pressure	Shift toward newer INSTIs may reduce sales of GENVOYA
Biosimilar entry	Significant price erosion anticipated in key markets
Pipeline developments	New formulations or combination therapies could mitigate decline

---

4. Pricing, Reimbursement, and Regulatory Environment

Pricing in Key Markets

Market	Average Wholesale Price (AWP)	Reimbursement Dynamics	Patent Status
U.S.	~$40,000/year	Negotiated via PBMs, insurance coverage	Expires 2027 [3]
EU	€30,000–€35,000/year	National reimbursement policies	Patent extends at least through 2027
Japan	¥4,000,000–¥4,500,000/year	National health insurance coverage	Patent expires 2027

Regulatory Trends

• Streamlined Approvals: Regulatory agencies favor FDC therapies with proven efficacy.
• Biosimilar Approvals: Increasing in mature markets, driving price competition.
• Global Access: Initiatives aimed at expanding access in developing nations, often involving tiered pricing.

---

5. Future Outlook and Strategic Considerations

Market Challenges

• Patent expiry and biosimilar competition threaten revenue streams.
• Rapid technological advances necessitate ongoing R&D investment.
• Pricing pressures and commitment to affordability impact margins.

Opportunities

• Expanding into emerging markets with tailored strategies.
• Developing next-generation formulations with improved safety profiles.
• Combining data analytics for personalized HIV therapy management.

Strategic Recommendations

Action	Rationale
Accelerate pipeline innovations	To surpass existing competitors and maintain market share
Engage in strategic licensing	To extend patent protections or secure biosimilars advantage
Expand in emerging markets	To offset revenue declines in mature markets
Focus on adherence solutions	To improve patient outcomes and brand loyalty

---

Conclusion

GENVOYA remains a commercially valuable asset within Gilead’s portfolio, supported by its efficacy, safety, and convenience profile. However, approaching patent expiry in 2027 poses significant revenue risks due to intensifying biosimilar competition. Investment decisions should weigh its current market dominance against upcoming patent cliffs, regional market growth prospects, and competitive innovations. Active strategic positioning—focused on pipeline development, regional expansion, and pricing agility—will determine its future financial trajectory.

---

Key Takeaways

• GENVOYA’s global sales are projected to plateau post-2026, with potential decline after patent expiration in 2027.
• Competition from newer INSTIs like Biktarvy and generics threatens market share.
• Pricing and reimbursement nuances significantly influence revenue sustainability.
• Regional expansion, especially in emerging markets, offers growth opportunities to offset mature market declines.
• Ongoing pipeline innovation and strategic collaborations are critical to maintaining long-term investment value.

---

FAQs

Q1: When will GENVOYA face generic competition?
A: Patent protection is expected to expire in the U.S. in 2027, after which biosimilars and generics are likely to penetrate the market substantially.

Q2: How does GENVOYA compare with Biktarvy in terms of market positioning?
A: Biktarvy, approved in 2018, offers a higher barrier to resistance, fewer drug interactions, and has gained rapid market share, posing a competitive threat to GENVOYA.

Q3: What regional markets offer the most growth potential for GENVOYA?
A: Asia-Pacific, Africa, and Latin America present significant expansion opportunities due to increasing HIV prevalence and expanding healthcare infrastructure.

Q4: How does pricing impact the future profitability of GENVOYA?
A: Price reductions driven by biosimilar entry and policy shifts in favor of affordability likely will decrease royalties and revenues post-2027.

Q5: What strategic steps should Gilead undertake to sustain revenue?
A: Gilead should accelerate pipeline innovation, seek licensing agreements, expand in emerging markets, and enhance adherence technologies.

---

References

[1] Grand View Research. HIV Therapeutics Market Size, Share & Trends Analysis Report. 2022.

[2] IQVIA Reports. Global HIV Market Insights. 2022.

[3] U.S. Patent and Trademark Office. Patent Status and Lifespans for HIV Drugs. 2022.